InMed to Present at the 34th Annual Roth Conference
March 08 2022 - 7:30AM
via InvestorWire --
InMed Pharmaceuticals Inc.
(“InMed” or the “Company”) (Nasdaq: INM), a leader in the research,
development, manufacturing and commercialization of rare
cannabinoids, today announces that Eric A. Adams, InMed’s President
and Chief Executive Officer, will be presenting at the 34th Annual
Roth Conference being held March 13-15, 2022.
Mr. Eric A. Adams, InMed’s President and Chief
Executive Officer, will be hosting a fireside chat with Scoth
Henry, Managing Director and Head of Pharmaceuticals Research
at Roth Capital Partners, on Tuesday, March 15, 2022, at 09:30 AM
ET/12:30 PM PT. A webcast will be made available to investors
following the event. The webcast link can be found in the investor
relations section of the Company’s website at
https://investors.inmedpharma.com/events/event-details/inmed-presenting-34th-annual-roth-conference.
In addition to the live fireside chat, InMed’s
virtual Roth Conference presentation is now available on-demand.
Investors can view the on-demand webcast presentation here:
https://wsw.com/webcast/roth43/inm/1677456.
This year’s event will consist of 1-on-1 / small
group meetings, analyst-selected fireside chats, thematic industry
panels, and on-demand presentations by executive management from
approximately 400 private and public companies.
To learn more and submit a registration request,
visit https://ibn.fm/ROTH2022Registration.
About Roth Capital PartnersRoth
Capital Partners Roth Capital Partners, LLC (Roth) is a
relationship-driven investment bank focused on serving emerging
growth companies and their investors. As a full-service investment
bank, Roth provides capital raising, M&A advisory, analytical
research, trading, market-making services and corporate access.
Headquartered in Newport Beach, California, Roth is privately held
and owned by its employees and maintains offices throughout the
U.S. For more information on Roth, please visit www.roth.com.
About InMed:
InMed Pharmaceuticals is a global leader in the research,
development, manufacturing and commercialization of rare
cannabinoids. Together with its subsidiary BayMedica LLC, the
Company has unparalleled cannabinoid manufacturing capabilities to
serve a spectrum of consumer markets, including pharmaceutical and
health and wellness. InMed is also a clinical-stage company
developing a pipeline of rare cannabinoid therapeutics and
dedicated to delivering new treatment alternatives to patients that
may benefit from cannabinoid-based pharmaceutical drugs. For more
information, visit www.inmedpharma.com and
www.baymedica.com.
Investor Contact: Colin ClancySenior Director,
Investor RelationsT: +1.604.416.0999E:
cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: being a global leader in the research,
development, manufacturing and development of rare cannabinoids;
having unparalleled cannabinoid manufacturing capabilities to serve
a spectrum of consumer markets, including pharmaceutical and health
and wellness; presenting at the 34th Annual Roth Conference being
held March 13-15, 2022; and developing a pipeline of rare
cannabinoid therapeutics and dedicated to delivering new treatment
alternatives to patients that may benefit from cannabinoid-based
pharmaceutical drugs.
With respect to the forward-looking information
contained in this news release, InMed has made numerous
assumptions. While InMed considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. A complete discussion
of the risks and uncertainties facing InMed’s stand-alone business
is disclosed in InMed’s Annual Report on Form 10-K and other
filings with the Security and Exchange Commission on
www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
Corporate CommunicationsIBN
(InvestorBrandNetwork) Los Angeles, California
www.InvestorBrandNetwork.com 310.299.1717 Office
Editor@InvestorBrandNetwork.com
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Mar 2024 to Apr 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2023 to Apr 2024